
Chinese General Practice ›› 2020, Vol. 23 ›› Issue (30): 3789-3797.DOI: 10.12114/j.issn.1007-9572.2020.00.209
Special Issue: 呼吸疾病文章合辑
• Monographic Research • Previous Articles Next Articles
Published:2020-10-20
Online:2020-10-20
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2020.00.209
| [1]归巧娣,张华,宫艳艳,等.陕西省临床分离革兰阴性菌的分布与耐药分析[J].国际检验医学杂志,2019,40(1):85-88.DOI:10.3969/j.issn.1673-4130.2019.01.022. [2]胡付品,朱德妹,汪复,等.2011年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2012,12(5):321-329.DOI:10.3969/j.issn.1009-7708.2012.05.001. HU F P,ZHU D M,WANG F,et al.2011 CHINET surveillance of bacterial resistance in China[J].Chinese Journal of Infection and Chemotherapy,2012,12(5):321-329.DOI:10.3969/j.issn.1009-7708.2012.05.001. [3]程秦,沈宁,郑佳佳,等.耐碳青霉烯肺炎克雷伯菌肺炎患者死亡相关因素分析[J].中国临床药理学杂志,2018,34(14):1703-1706.DOI:10.13699/j.cnki.1001-6821.2018.14.034. CHENG Q,SHEN N,ZHENG J J,et al.Analysis of mortality-related factors in pneumonia patients with carbapenem-resistant Klebsiella pneumoniae infection[J].The Chinese Journal of Clinical Pharmacology,2018,34(14):1703-1706.DOI:10.13699/j.cnki.1001-6821.2018.14.034. [4]黄静静,崔巍.ICU肺炎克雷伯菌感染患者耐碳青霉烯类及预后的相关因素分析[J].浙江医学,2015,37(20):1677-1680. HUANG J J,CUI W.Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infection in ICU[J].Zhejiang Medical Journal,2015,37(20):1677-1680. [5]杨修文,崔俊昌,赵进,等.碳青霉烯类耐药肺炎克雷伯菌血流感染的临床特征与死亡危险因素分析[J].中国感染与化疗杂志,2018,18(2):142-149.DOI:10.16718/j.1009-7708.2018.02.004. YANG X W,CUI J C,ZHAO J,et al.Clinical characteristics of carbapenem-resistant Klebsiella pneumoniae bloodstream infection and the risk factors of mortality[J].Chinese Journal of Infection and Chemotherapy,2018,18(2):142-149.DOI:10.16718/j.1009-7708.2018.02.004. [6]YIGIT H,QUEENAN A M,ANDERSON G J,et al.Novel carbapenem-hydrolyzing beta-lactamase,KPC-1,from a carbapenem-resistant strain of Klebsiella pneumoniae[J].Antimicrob Agents Chemother,2001,45(4):1151-1161.DOI:10.1128/AAC.45.4.1151-1161.2001. [7]SBRANA F,MALACARNE P,VIAGGI B,et al.Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K.pneumoniae in intensive care unit[J].Clin Infect Dis,2013,56(5):697-700.DOI:10.1093/cid/cis969. [8]CANTON R,AKOVA M,CARMELI Y,et al.Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe[J].Clin Microbiol Infect,2012,18(5):413-431.DOI:10.1111/j.1469-0691.2012.03821.x. [9]TUMBARELLO M,VIALE P,VISCOLI C,et al.Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K.pneumoniae:importance of combination therapy[J].Clin Infect Dis,2012,55(7):943-950.DOI:10.1093/cid/cis588. [10]PATEL G,HUPRIKAR S,FACTOR S H,et al.Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies[J].Infect Control Hosp Epidemiol,2008,29(12):1099-1106.DOI:10.1086/592412. [11]钟秀君,汤杰,顾克菊,等.耐碳青霉烯类肺炎克雷伯菌的耐药性及预后相关因素分析[J].中华医院感染学杂志,2017,27(6):1201-1205. ZHONG X J,TANG J,GU K J,et al.Drug resistance and prognosis factors of carbapenem-resistant Klebsieila pneumonia[J].Chinese Journal of Nosocomiology,2017,27(6):1201-1205. [12]叶相如,胡必杰,周春妹,等.耐碳青霉烯类肺炎克雷伯菌感染与定植患者预后相关因素分析[J].中华医院感染学杂志,2015,25(11):2489-2491.DOI:10.11816/cn.ni.2015-150575. YE X R,HU B J,ZHOU C M,et al.Related risk factors for prognosis of patients with carbapenem-resistant Klebsiella pneumoniae infection or colonization[J].Chinese Journal of Nosocomiology,2015,25(11):2489-2491.DOI:10.11816/cn.ni.2015-150575. [13]TUMBARELLO M,TRECARICHI E M,DE ROSA F G,et al.Infections caused by KPC-producing Klebsiella pneumoniae:differences in therapy and mortality in a multicentre study[J].J Antimicrob Chemother,2015,70(7):2133-2143.DOI:10.1093/jac/dkv086. [14]DAIKOS G L,TSAOUSI S,TZOUVELEKIS L S,et al.Carbapenemase-producing Klebsiella pneumoniae bloodstream infections:lowering mortality by antibiotic combination schemes and the role of carbapenems[J].Antimicrob Agents Chemother,2014,58(4):2322-2328.DOI:10.1128/AAC.02166-13. [15]KNAUS W A,DRAPER E A,WAGNER D P,et al.Apache Ⅱ:a severity of disease classification system[J].Crit Care Med,1985,13(10):818-829. [16]倪世杰.APACHE Ⅱ评分系统在ICU护理人力资源配置中的应用[J].转化医学电子杂志,2015,2(8):130,132. [17]孟新科,邓跃林.APACHEⅡ与SAPSⅡ评分系统对急诊内科危重患者病情评估价值的比较[J].中国危重病急救医学,2001,13(12):751-755.DOI:10.3760/j.issn:1003-0603.2001.12.014. [18]李娇,商临萍,郭红菊,等.综合ICU多重耐药菌医院感染的风险模型构建[J].中国感染控制杂志,2016,15(10):730-734.DOI:10.3969/j.issn.1671-9638.2016.10.003. LI J,SHANG L P,GUO H J,et al.Construction of risk model for healthcare-associated infection with multi-drug-resistant organisms in general intensive care unit[J].Chinese Journal of Infection Control,2016,15(10):730-734.DOI:10.3969/j.issn.1671-9638.2016.10.003. [19]刘雪媛.预测危重创伤患者死亡的一种新评分系统:死亡预警评分的预测价值[D].遵义:遵义医学院,2016. LIU X Y.A new score system for prediction of death in patients with severe trauma:the value of death warning sore[D].Zunyi:Zunyi Medcial College,2016. [20]郭磊磊,秦红英,张艺,等.重症监护病区医院感染风险预测模型构建[J].中华医院感染学杂志,2019,29(8):1240-1245. GUO L L,QIN H Y,ZHANG Y,et al.Construction of risk prediction model for nosocomial infection in intensive care unit[J].Chinese Journal of Nosocomiology,2019,29(8):1240-1245. [21]TUMBARELLO M,VIALE P,BASSETTI M,et al.Infections caused by KPC-producing Klebsiella pneumoniae:differences in therapy and mortality in a multicentre study——authors' response[J].J Antimicrob Chemother,2015,70(10):2922.DOI:10.1093/jac/dkv200. [22]张琼,刘锦华,李鹤琴,等.血管活性药物肾上腺素对重症感染性休克患者肾功能及血流动力学指标的影响[J].解放军预防医学杂志,2019,37(2):48-50.DOI:10.13704/j.cnki.jyyx.2019.02.018. [23]张晶,刘磊.多巴胺和去甲肾上腺素对感染性休克患者血流动力学和组织氧代谢的影响评价[J].抗感染药学,2017,14(1):68-70.DOI:10.13493/j.issn.1672-7878.2017.01-019. [24]STOLK R F,VAN DER POLL T,ANGUS D C,et al.Potentially inadvertent immunomodulation:norepinephrine use in sepsis[J].Am J Respir Crit Care Med,2016,194(5):550-558.DOI:10.1164/rccm.201604-0862CP. [25]ANANTASIT N,BOYD J H,WALLEY K R,et al.Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock[J].Crit Care Med,2014,42(8):1812-1820.DOI:10.1097/CCM.0000000000000333. [26]VINCENT J L,MORENO R,TAKALA J,et al.The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure[J].Intensive Care Med,1996,22(7):707-710.DOI:10.1007/s001340050156. [27]MARSHALL J C,COOK D J,CHRISTOU N V,et al.Multiple organ dysfunction score:a reliable descriptor of a complex clinical outcome[J].Crit Care Med,1995,23(10):1638-1652.DOI:10.1097/00003246-199510000-00007. [28]王今达,王宝恩.多脏器功能失常综合征(MODS)病情分期诊断及严重程度评分标准(经庐山’95全国危重病急救医学学术会讨论通过)[J].中国危重病急救医学,1995,7(6):346-347. [29]张淑文,王超,阴赪宏,等.多器官功能障碍综合征诊断标准与病情严重度评分系统的多中心临床研究[J].中国危重病急救医学,2004,16(6):328-332.DOI:10.3760/j.issn:1003-0603.2004.06.003. [30]肖婷婷,喻玮,牛天水,等.ICU患者碳青霉烯类不敏感肺炎克雷伯菌血流感染危险因素及预后分析[J].中国抗生素杂志,2017,42(12):1090-1096.DOI:10.3969/j.issn.1001-8689.2017.12.013. XIAO T T,YU W,NIU T S,et al.A retrospective study of risk factors and outcome for carbapenem-nonsusceptible Klebsiella pneumoniae bacteremia among ICU patients[J].Chinese Journal of Antibiotics,2017,42(12):1090-1096.DOI:10.3969/j.issn.1001-8689.2017.12.013. [31]贾征.抗生素耐药性防治措施[J].国外医药:抗生素分册,2019,40(1):5-8.DOI:10.3969/j.issn.1001-8751.2019.01.003. JIA Z.Control steps for the antibiotic resistance[J].World Notes on Antibiotics,2019,40(1):5-8.DOI:10.3969/j.issn.1001-8751.2019.01.003. [32]黄荣才,高胜涛,范士杰,等.畜禽粪污源抗生素及耐药基因在环境中的归趋[J].生物技术进展,2019,9(2):146-151.DOI:10.19586/j.2095-2341.2018.0137. HUANG R C,GAO S T,FAN S J,et al.Environmental fate of antibiotics and antibiotic resistance genes in animal manure[J].Current Biotechnology,2019,9(2):146-151.DOI:10.19586/j.2095-2341.2018.0137. [33]谢朝云,熊芸,覃家露,等.某院2011—2017年非痰标本产AmpC酶阴沟肠杆菌的临床分布及耐药性分析[J].中国药房,2018,29(8):1069-1073. XIE C Y,XIONG Y,QIN J L,et al.Analysis of clinical distribution and drug resistance of non-sputum specimen AmpC enzyme-producing Enterobacter cloacae in a hospital during 2011—2017[J].China Pharmacy,2018,29(8):1069-1073. [34]韦海荣.抗生素耐药性的经济影响研究进展[J].中外医学研究,2019,17(1):186-188.DOI:10.14033/j.cnki.cfmr.2019.01.088. [35]HUANG W Z,QIAO F,ZHANG Y Y,et al.In-hospital medical costs of infections caused by carbapenem-resistant Klebsiella pneumoniae[J].Clin Infect Dis,2018,67(suppl 2):S225-230.DOI:10.1093/cid/ciy642. [36]VARGAS-ALZATE C A,HIGUITA-GUTIERREZ L F,LOPEZ-LOPEZ L,et al.High excess costs of infections caused by carbapenem-resistant Gram-negative bacilli in an endemic region[J].Int J Antimicrob Agents,2018,51(4):601-607.DOI:10.1016/j.ijantimicag.2017.12.012. [37]BARTSCH S M,MCKINNELL J A,MUELLER L E,et al.Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States[J].Clin Microbiol Infect,2017,23(1):e9-48.DOI:10.1016/j.cmi.2016.09.003. [38]周旸,张陆,王子华,等.抗生素耐药性的多重风险因子及针对性管控策略[J].微生物学报,2018,58(11):2040-2050.DOI:10.13343/j.cnki.wsxb.20180337. ZHOU Y,ZHANG L,WANG Z H,et al.Key risk factors of antibiotic resistance ecology and targeted control strategies[J].Acta Microbiologica Sinica,2018,58(11):2040-2050.DOI:10.13343/j.cnki.wsxb.20180337. [39]游佳,李爱阳,王森林,等.SPSS Modeler在脑卒中患者预后建模中的应用[J].中国医疗设备,2018,33(10):60-63.DOI:10.3969/j.issn.1674-1633.2018.10.015. YOU J,LI A Y,WANG S L,et al.Application of SPSS modeler in predicting the mortality risk of hospitalized patients with stroke[J].China Medical Devices,2018,33(10):60-63.DOI:10.3969/j.issn.1674-1633.2018.10.015. [40]杨绳文,刘志敏,刘尚雨,等.心脏再同步化治疗患者临床预后风险评分系统的构建与验证[J].中国循环杂志,2017,32(8):761-765.DOI:10.3969/j.issn.1000-3614.2017.08.008. YANG S W,LIU Z M,LIU S Y,et al.The derivation and validation of a scoring system for clinical prognosis in patients releiving cardiac resynchronization therapy[J].Chinese Circulation Journal,2017,32(8):761-765.DOI:10.3969/j.issn.1000-3614.2017.08.008. [41]李兴杰,孙宇,殷商启,等.重庆市某二甲医院创伤患者发生MODS简易预警评分的建立[J].中国中西医结合急救杂志,2018,25(4):358-362.DOI:10.3969/j.issn.1008-9691.2018.04.006. LI X J,SUN Y,YIN S Q,et al.Establishment of a simple early warning score for traumatic patients with onset of multiple organ dysfunction syndrome in a general hospital of grade ⅡA in Chongqing City[J].Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care,2018,25(4):358-362.DOI:10.3969/j.issn.1008-9691.2018.04.006. [42]姚运海,甘建和,赵卫峰.4种评分系统对肝硬化合并感染患者预后的评估价值[J].临床肝胆病杂志,2019,35(1):87-91.DOI:10.3969/j.issn.1001-5256.2019.01.016. YAO Y H,GAN J H,ZHAO W F.Value of four scoring systems in evaluating the prognosis of cirrhotic patients with infection[J].Journal of Clinical Hepatology,2019,35(1):87-91.DOI:10.3969/j.issn.1001-5256.2019.01.016. [43]宋先荣,孟丽,苑星,等.建立Stanford A型主动脉夹层围手术期风险评估系统的探索[J].中华胸心血管外科杂志,2018,34(6):350-355.DOI:10.3760/cma.j.issn.1001-4497.2018.06.006. SONG X R,MENG L,YUAN X,et al.Establishment of perioperative risk assessment system for type A aortic dissection[J].Chinese Journal of Thoracic and Cardiovascular Surgery,2018,34(6):350-355.DOI:10.3760/cma.j.issn.1001-4497.2018.06.006. [44]董绉绉,石林惠,叶龙强,等.肝移植术后肾脏替代治疗的危险因素分析及初始治疗时机对预后的影响[J].中华危重病急救医学,2018,30(11):1056-1060.DOI:10.3760/cma.j.issn.2095-4352.2018.11.009. DONG Z Z,SHI L H,YE L Q,et al.Risk factors analysis of renal replacement therapy after liver transplantation and prognosis effect of initial treatment time[J].Chinese Critical Care Medicine,2018,30(11):1056-1060.DOI:10.3760/cma.j.issn.2095-4352.2018.11.009. [45]SURESH K,TAYLOR J M G,SPRATT D E,et al.Comparison of joint modeling and landmarking for dynamic prediction under an illness-death model[J].Biom J,2017,59(6):1277-1300.DOI:10.1002/bimj.201600235. [46]李丽霞,王彤,范逢曦.BP神经网络与logistic回归的比较研究[J].中国卫生统计,2005,22(3):138-140.DOI:10.3969/j.issn.1002-3674.2005.03.003. [47]郑伟.Cox比例风险模型在泌尿外科手术后感染研究中的应用[J].右江医学,2012,40(5):633-635.DOI:10.3969/j.issn.1003-1383.2012.05.008. ZHENG W.Appication of Cox proportional hazards model in the research of urological postoperative infection[J].Youjiang Medical Journal,2012,40(5):633-635.DOI:10.3969/j.issn.1003-1383.2012.05.008. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||